Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|April 7, 2015

SAFC Introduces New Media System

The system is compatible with a wide range of industrial CHO cell lines.


SAFC announced on Apr. 7, 2015 that the company has introduced a new fed-batch medium, EX-CELL Advanced CHO Fed-batch System. The new basal media, available with and without glucose, is said to offer “high titers, robust scalability, and uncompromised protein quality,” according to a statement.

"At SAFC we recognize our customers' needs are constantly changing," said Deb Stutz, director of biopharm marketing at SAFC. "We are delighted to launch this product in response to market needs for new levels of speed and performance, while continuing to provide the confidence of a secure and transparent supply chain."

Fed-batch production processes have improved upstream process titers dramatically in recent years. According to some sources, companies have been able to attain antibody concentrations of up to 10–13 g/L using fed-batch processes.  Although batch-fed stainless steel bioreactors remain the preferred choice for the commercial manufacture of therapeutics, according to research by BioPlan Associates, continuous bioprocessing is also emerging as a viable option for upstream activities.

Source: SAFC


Related to this article

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.